News

Number of news items returned: 201 to 220 records of 422

KOEL India and BioCube™ Corporation Ratify Manufacturing and Distribution agreement

14 March 2016

(14162 views)

On March 9th 2016, the Board of Directors of Kirloskar Oil Engines Limited (KOEL) ratified a license agreement proposed between ...

Early Successes For Our Clients in 2016 - Funding Strategies Connect March 2016

11 March 2016

(13489 views)

 Early Successes For Our Clients in 2016 - Funding Strategies Connect March 2016 Dear Readers, I have great progress to report for ...

Canada's Prime Minister Visits the BioCube

08 March 2016

(13404 views)

 "Justin Trudeau, Prime Minister of Canada visits the BioCube™ The BioCube Corporation was delighted to have The Right Honourable Justin Trudeau, ...

BlueMount Capital: Finalist of the 23rd Annual Australia-China Business Awards

08 March 2016

(13145 views)

  "23rd Annual Australia-China Business Awards Finalists Announced Shanghai: 8th March – The AustCham Westpac Australia-China Business Awards has received a record-breaking ...

Uchoose continues path of growth and operational expansion, establishes new and exciting line of business and welcomes leading industry authority to advisory role.

04 March 2016

(14489 views)

"Uchoose again confirms its trajectory of growth with the favourable half yearly results being underpinned by some exciting developments in ...

Appee Ltd Announcement

04 March 2016

(13185 views)

"Appee Ltd has drawn international attention by signing its first USA customer - Automobile Club of Southern California (a member ...

50% month-on-month revenue growth, expanding team and China

29 February 2016

(14391 views)

"Squirel Ltd (“Squirel” or the “Company”) is pleased to announce the appointment of Fiona Hong a senior financial services professional ...

Australian Trading & Investment Corporation Ltd Announcement

23 February 2016

(15539 views)

"... Foundation ready for growth New Sales Manager appointed   ...Additional expenditure has been focused on expansion. We have secured premises in the CBD ...

Appee new 2016!

19 February 2016

(14069 views)

"2015 was a year of firsts for appee. From our first beta release of the appee product and website, to ...

Ocular Robotics Appoints US Based Leading Global Supplier of Autonomy Components as Distribution Partner

18 February 2016

(13523 views)

"AutonomouStuff the leading supplier of components to the rapidly growing autonomy sector has been appointed as an Ocular Robotics distributor ...

BioCube commissions machine in Congo for Palm Oil conversion to Biodiesel

30 January 2016

(14548 views)

"The BioCube Corporation (BC) has successfully commissioned a BioCube 250 for Feronia Inc at its Yaligimba Palm Oil plantation in the ...

2016 So Far, Not So Good

29 January 2016

(14487 views)

"... Whilst 2015 may have finished with a Santa rally in capital markets, 2016 has started horribly with losses across the ...

Gartner lists Opmantek in 2016 Market Guide for Network Automation

27 January 2016

(15171 views)

"Opmantek (ASSOB:OMK) a multi award winning provider of IT infrastructure management and Audit solutions, today announced that it has been ...

Australian Trading & Investment Corporation Ltd – Update

21 January 2016

(14257 views)

"To all interested parties, welcome to an exciting 2016! ...Since our last update we’re finding tremendous traction in setting the foundation ...

Equity Crowdfunding and Investment Opportunties

29 December 2015

(14682 views)

Looking to assist investors and private businesses in 2016 - from the team at Funding Strategies.   Funding Strategies provides Corporate ...

2015: An Inflection Point?

16 December 2015

(14273 views)

"As 2015 draws to a close the year we thought we’d recap the year and look at what’s on the ...

CRe8 Home & Finance Ltd – last chance to participate in this innovative company

14 December 2015

(14219 views)

"...CRe8 has had a stellar 2015, the highlights of which are listed below; Glenvill Homes (CRe8’s home builder partner) committed to ...

Opmantek Sales growth a new record

14 December 2015

(14056 views)

"Opmantek (ASSOB:OMK) has continued on its high growth trajectory signing significant customer agreements in November throughout the USA and Latin ...

Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project, Rovina Project Shows Off Digital Reconstruction of the ARIS Priscilla Catacombs

08 December 2015

(14531 views)

"Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project.   Aerospace company GMV have been awarded ...

Australian Trading and Investment Corporation Investor Update

07 December 2015

(14112 views)

"To all interested parties, Since our last update there have been some exciting updates, as listed below:   ..Our model portfolio increased by ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625